Law360, New York (February 1, 2016, 8:29 PM EST) -- The Federal Circuit on Monday affirmed a lower court's decision that four patents on Purdue Pharma LP's painkiller OxyContin are invalid as anticipated or obvious in a win for four generics makers planning their own version of the drug.
The appeals court said that it was persuaded by the conclusions reached in 2014 by Senior Judge Sidney H. Stein of the Southern District of New York following a three-week bench trial over Teva Pharmaceuticals USA Inc.'s planned generic OxyContin. It also affirmed the judge's decision to then dismiss Purdue's similar suits against Amneal Pharmaceuticals LLC, Epic Pharma LLC and Mylan Inc. over...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!